Capsid inhibitors Archives

Novartis Taps into Voyager’s TRACER Platform in Deal Valued at $1.7 Billion

Adeno-Associated Virus (AAV), Business, Capsid inhibitors, CNS, Collaborations, Gene Therapy, Novartis, Partnerships, R&D

Voyager Therapeutics partnered with Novartis in a potential $1.7 billion deal. The collaboration will enable Novartis to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor

Antiretrovirals, Capsid inhibitors, Clinical Data, Clinical Trials, Gilead, HIV infections, Multi-drug resistant HIV-1 infection, R&D

Gilead Sciences Inc. announced new results from the Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.

Gilead’s Lenacapavir Shows Promise for Multidrug-Resistant HIV in Phase II/III Trial

Breakthrough Therapy Designation, Capsid inhibitors, Clinical Trials, Drug Resistance, Gilead, HIV-1, Primary Endpoints, R&D, Topline Data

Topline results from Gilead Sciences’ Phase II/III CAPELLA trial show that treatment with the company’s long-acting HIV-1 capsid inhibitor lenacapavir reduces HIV viral load better than placebo in heavily treated patients living with multidrug resistant HIV-1 infection.